Dennis Thiele's Contact Details

Dennis Thiele's Company Details

Sisu Pharma

N/A, N/A, US • 5 - 9 Employees
BioTech/Drugs

Sisu's Heat Shock Factor 1 (HSF1) targeting platform, HI-LiTe, enables the discovery and design of small molecules that bind directly to HSF1. Sisu has developed compounds that selectively stimulate the degradation of the active, nuclear form of HSF1. Inhibitors of this target have long been sought and Sisu is the only company whose technology enables the discovery of direct HSF1 interacting compounds. When cellular stress arises in normal cells, HSF1 is quickly activated to preserve cellular function, triggering the expression of stress-resistance genes. HSF1 then returns to its normal, inactive state. Advanced and metastatic cancers (e.g. Prostate, Breast, Lung) chronically activate HSF1 to exploit it's ability to to support cancer cell growth, survival and metastasis. Sisu's HI-LiTe technology platform enables us to selectively target the active form of HSF1 that cancer cells that rely on, while sparing normal cells where HSF1 is inactive.